Vinva Investment Management Ltd Makes New $1.03 Million Investment in DexCom, Inc. (NASDAQ:DXCM)

Vinva Investment Management Ltd bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 13,207 shares of the medical device company's stock, valued at approximately $1,030,000.

Other institutional investors also recently modified their holdings of the company. Blue Whale Capital LLP increased its holdings in DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company's stock worth $15,821,000 after buying an additional 113,000 shares during the last quarter. Motley Fool Asset Management LLC increased its stake in shares of DexCom by 168.7% during the 3rd quarter. Motley Fool Asset Management LLC now owns 272,622 shares of the medical device company's stock worth $17,993,000 after purchasing an additional 171,150 shares during the last quarter. Watts Gwilliam & Co. LLC bought a new stake in shares of DexCom in the 4th quarter worth approximately $3,334,000. Congress Asset Management Co. raised its holdings in shares of DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the period. Finally, Janney Montgomery Scott LLC lifted its stake in DexCom by 2,226.6% in the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company's stock valued at $18,085,000 after purchasing an additional 222,548 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the business's stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the transaction, the chief executive officer now owns 319,037 shares of the company's stock, valued at $27,727,505.67. The trade was a 9.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at approximately $7,259,244.66. This trade represents a 2.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. 0.30% of the stock is owned by corporate insiders.

Remove Ads

DexCom Price Performance

Shares of DexCom stock traded down $1.77 during trading on Tuesday, hitting $73.55. The stock had a trading volume of 3,240,370 shares, compared to its average volume of 3,915,036. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a market cap of $28.74 billion, a price-to-earnings ratio of 51.43, a P/E/G ratio of 2.30 and a beta of 1.28. The business's 50-day moving average is $83.24 and its 200 day moving average is $77.07.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DXCM. Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday. Robert W. Baird upgraded DexCom from a "neutral" rating to an "outperform" rating and boosted their price objective for the company from $86.00 to $104.00 in a research note on Thursday, January 16th. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research report on Friday, February 14th. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $99.82.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.